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ABSTRACT 
For the creation of scaffolds in tissue engineering applications, it is essential to control the 
physical morphology of fibres and to choose compositions which do not disturb normal 
physiological function. Collagen, the most abundant protein in the human body, is a well-
established biopolymer used in electrospinning compositions. It shows high in-vivo stability 
and is able to maintain a high biomechanical strength over time. In this study, the effects of 
collagen type I in polylactic acid-drug electrospun scaffolds for tissue engineering 
applications are examined. The samples produced were subsequently characterised using a 
range of techniques. Scanning electron microscopy analysis shows that the fibre 
morphologies varied across PLA-drug and PLA-collagen-drug samples – the addition of 
collagen caused a decrease in average fibre diameter by nearly half, and produced 
nanofibres. Atomic force microscopy imaging revealed collagen-banding patterns which 
show the successful integration of collagen with PLA. Solid-state characterisation suggested 
a chemical interaction between PLA and drug compounds, irgasan and levofloxacin, and the 
collagen increased the amorphous regions within the samples. Surface energy analysis of 
drug powders showed a higher dispersive surface energy of levofloxacin compared with 
irgasan, and contact angle goniometry showed an increase in hydrophobicity in PLA-
collagen-drug samples. The antibacterial studies showed a high efficacy of resistance against 
the growth of both E. coli and S. Aureus, except with PLA-collagen-LEVO which showed a 
regrowth of bacteria after 48 h. This can be attributed to the low drug release percentage 
incorporated into the nanofibre during the in vitro release study. However, the studies did 
show that collagen helped shift both drugs into sustained release behaviour. These ideal 
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modifications to electrospun scaffolds may prove useful in further research regarding the 
acceptance of human tissue by inhibiting the potential for bacterial infection. 
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1. INTRODUCTION 
Within the field of tissue engineering, there are a number of different applications that can 
be explored relating to the combination of synthetic and natural polymers, and integration 
with various active pharmaceutical ingredients. For example, surgical wound closure 
involves the bringing together of opposing surfaces using glues, staples and/or sutures.  The 
re-joined tissues then undergo a primary hyper-proliferative stage, characterised by clot 
formation and the recruitment of inflammatory cells (macrophages) into the wound1. 
Secretion of local tissue mediators encourages cell migration and begins the process of scar 
formation2. Wound contraction, a result of tissue remodelling, increases the tensile strength 
of skin across lesions and increases (or decreases) the risk of ruptures. During the healing 
stage, the tissue is open to infection itself and as a pathway into deeper tissue structures. 
Infection can result in significant complications (e.g. prolonged systemic antibiotic 
administration, re-operation for debridement) for the patient in the short and long-term.  In 
supporting healing, the purpose of an added matrix task may be to provide tensile strength, 
to encourage controlled epithelialisation and new vascular growth and to decrease the 
formation of bacterial biofilms. The fabrication of scaffolds for wound repair has become 
important, especially the formation of tissue-specific scaffolds3. 
For the creation of scaffolds it is essential to mimic the chemical composition, the physical 
morphology, and the biological functions of the human body4. Scaffolds can be created 
using synthetic polymers (e.g. polycaprolactone) or natural polymers (e.g. chitosan), or a 
combination of both – the addition of natural polymers can be highly advantageous as these 
may avoid the stimulation of chronic inflammation, immunological reactions and toxicity5. 
An example of a natural polymer is collagen, which is the most abundant protein in the 
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human body, a key element of the extracellular matrix (ECM), and imparts structural 
integrity and tensile strength to tissues6. Using collagen in scaffolds has been previously 
shown to show a high in vivo stability and is able to maintain a high biomechanical strength 
over time7.  
One method that is commonly used to fabricate scaffolds for tissue engineering is 
electrospinning. The technique utilises electrostatic forces to stretch a dilute polymer 
solution as it solidifies8. It is an ideal micro- and nanofibre fabrication technique for tissue 
engineering, as the fibres within the resulting scaffold closely mimic the size and structure of 
the native extracellular matrix9 and the use of solvent and aqueous based systems are 
useful for the integration of biological compounds, such as collagen. Various practices of 
electrospinning collagen, including collagen-elastin blends10, collagen-polycaprolactone 
scaffolds for vascular tissue engineering11, and fibrinogen fibres which allows native 
deposits of collagen during cell growth12 have previously been studied. Despite these 
examples of electrospinning involving collagen, there is an apparent gap in the research 
concerning the integration of drugs in these electrospun scaffolds. The integration of drugs, 
such as antibiotics, with polymer-collagen blends may be critical in the future success of 
human tissue accepting the scaffolds; there are many clinical applications for scaffolds that 
require controlling growth of bacteria. For example, one of the requirements for controlling 
intra-abdominal infection is to maintain satisfactory levels of an antimicrobial drug during 
drug administration13. In this regard, the sustained release of drugs is critical to the success 
of the device. Sustained release of drugs with electrospun materials have been previously 
studied, including polylactic acid with diclofenac sodium (an anti-inflammatory agent)14, 
metronidazole-loaded polycaprolactone nanofibres15, and polyvinylidene fluoride with 
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enrofloxacin (antibiotic)16. Given the range of success there has been with electrospinning 
polymer with drug, and polymer-collagen blends, the next area of research should be to 
determine whether we can alter any of the characteristics of scaffolds with the inclusion of 
collagen, whether it be mechanical, chemical or drug release changes. 
The purpose of this study is to examine the physicochemical properties, bacterial response, 
drug loading and bio-functionalisation of electrospun scaffolds that have been prepared 
using Type I Collagen with a supporting synthetic polymer. The polymer chosen for this 
study is Polylactic-acid (PLA), a biodegradable and biocompatible polymer. It has been 
approved by the US Food & Drug Administration for safe clinical use as resorbable sutures17. 
PLA has also been used clinically for foot fractures (PLA pins)18, temporary implants19 and 
drug delivery carriers20.  In this study, solutions were modified by the addition of type I 
collagen. The matrix was loaded and electrospun with two drugs, triclosan (an antibacterial 
agent used commonly in soaps, detergents and surgical cleaning agents) or levofloxacin (a 
broad-spectrum quinolone antibiotic used commonly in clinical practice to treat 
gastrointestinal infections). The electrospun fibres were then characterised through various 
methods: the morphology of the electrospun fibres was characterised by scanning electron 
microscope (SEM) and Atomic Force Microscope (AFM), solid state characterisation was 
performed by x-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC), 
surface characterisation of the two drugs was investigated by surface energy analysis (SEA) 
and contact angle goniometry (CAG), and drug efficacy (e.g. in vitro release studies, 
antibacterial studies and time-of-flight secondary ion mass spectrometry (ToF-SIMS)). The 
results from this study should help to build a profile of data in order to aid future work with 
regards to tissue engineering research specific to the controlled release of drugs. 
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2. MATERIALS & METHODS 
2.1 Materials 
Polylactic acid (PLA) with a mixed molecular weight was the chosen polymer for this study 
and was used as purchased from the suppliers (Sigma-Aldrich, GF45989881), and the 
collagen used was type I from calf skin (Sigma-Aldrich, C9791). Irgasan (5-Chloro-2-(2,4-
dichlorophenoxy)phenol), Triclosan, >97%, (Sigma-Aldrich, 72779) and levofloxacin ((S)-9-
fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-
benzoxazine-6-carboxylic acid)  >98%, (Sigma-Aldrich, 28266) were obtained commercially. 
The solvents used for the electrospinning were also commercially purchased from Sigma-
Aldrich, specifically chloroform (anhydrous, containing amylenes as stabilizers grade, >99%), 
N,N-dimethylformamide (DMF, anhydrous grade 99.8%) and 1,1,1,3,3,3-hexafluoro-2-
propanol, (GC grade >99%).  
2.2 Preparation of PLA Solutions 
Investigations of the polymer-drug solutions prepared showed that the optimum w/w 
concentration for electrospinning was 8%. This particular concentration was used as 
previous experimentation revealed that higher concentrations did not result in suitable fibre 
formation (suitable meaning regular fibre diameters and no signs of beading, data not 
shown). PLA (8% w/w), and a 9:1 (w/w) ratio of chloroform (CLF) to N,N-dimethylformamide 
(DMF). For the formulations containing collagen type I, both polymers were solubilised in 
hexafluoropropanol (HFP) with a total polymer (collagen + PLA) concentration of 8%. PLA 
was blended with collagen containing 1% collagen (MPLA / [MCollagen + MPLA] x 100)21. Collagen 
at a 1% concentration was used as higher concentrations, in the range 2% to 10% w/w, 
yielded unstable and inconsistent fibre formations. 
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The solutions were mixed through 30 min in the centrifuge, a further 30 min in a sonicator 
and a final 1 h with a magnetic stirrer, which resulted in a solution that appeared 
homogeneous and composed of a single phase. The solution was left overnight, and a 
further 30 min of sonication was applied the following morning in order to confirm the 
uniformity of the solution. For the irgasan-loaded solutions, the same method was applied, 
at a concentration of 1% irgasan w/w. The concentration of the levofloxacin-loaded 
solutions was adjusted to 0.5% w/w to facilitate accurate measurement of the drug release 
profile.  All the solutions remained clear after preparation.  This process was based on the 
method used by Hall Barrientos et al (2016) for solution preparation22. 
2.3 Electrospinning 
Various scaffolds were fabricated for each polymeric solution, using an in-house 
electrospinning apparatus which consisted of a syringe pump (Harvard Apparatus PHD 2000 
infusion, US) and two 30kV high-voltage power supplies (Alpha III series, Brandenburg, UK). 
The polymer solution was loaded into a 5 mL glass syringe and fed through tubing with a 
metal needle tip attached at the end. The needle was clamped into place, to allow for a 
high-voltage supply to run through it – this allowed for an electric field to be created 
between the needle and the target plate. The syringe was clamped to a pump, which 
determined the specific injection flow rate of the polymeric solutions. For each of the three 
solutions (e.g. unloaded, irgasan loaded, and levofloxacin loaded), 3 varying flow rates of 
0.5, 1 and 1.5 mL h-1 were applied across varying voltages of 2 kV – 5 kV (across the needles) 
and 10 kV – 18 kV22. A 21 gauge needle, at a deposition distance of between 10 – 12 cm was 
used. The process was performed at ambient room temperature (approximately 21°C) with 
a relative humidity of between 2 – 4 % (electrospinning was not performed is the relative 
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humidity was greater than 5%). The solution was electrospun onto the target that was 
covered with aluminium foil, in order for the final material to be removed and used for 
further characterisation. 
2.4 Scanning Electron Microscopy 
A scanning electron microscope (SEM) was used to determine the morphology and 
individual fibre diameter of the electrospun PLA solutions (PLA, PLA-IRG, PLA-LEVO, PLA-
Collagen, PLA-Collagen-IRG, and PLA-Collagen-LEVO). A Hitachi TM-1000 SEM was used to 
analyse various samples, in which the samples were mounted on an aluminium plate with 
conductive tape. Images of fibres were taken at various locations of each electrospun PLA 
scaffold in order to determine the overall uniformity of fibres (n=5). Prior to imaging, the 
samples were sputter coated with gold for 30 s using a Leica EM ACE200 vacuum coater, 
repeated three times in order to increase the conductivity of the samples. The samples were 
imaged in secondary electron mode at 5 kV. 
2.5 Mathematical analysis of fibre diameters 
Statistical comparisons of samples were conducted using SPSS 20.0 software package (SPSS 
Inc., Chicago IL, USA). Descriptive statistics, analysis of variance, Scheffé post hoc test and 
Kolgomorov-Smirnov test were performed using 50 individual fibre diameters of each 
samples obtained from the morphological analysis. 
2.6 Atomic Force Microscopy 
Further morphological analysis was undertaken through atomic force microscopy (AFM). A 
Multimode 8 microscope (Bruker, USA), with Scanasyst-Air probes (Bruker, USA) was used in 
Peak Force Quantitative Nano Mechanics (QNM) mode23. The imaging of the fibres was 
performed under ambient conditions, with a silicon cantilever probe (Bruker). The tip radius 
International Journal of Pharmaceutics 
 
11 
Ivan J. Hall Barrientos 
of the probe and the spring constant were calculated to be in the regions of 0.964 nm (18° 
tip half angle) and 0.3947 N/m, respectively. The scan sizes ranged from 200 nm to 25 µm, 
at a scan rate of 0.977 Hz with 512-sample resolution. The Roughness Average (Ra) values 
were determined by entering surface scanning data, and digital levelling algorithm values 
were determined using Nanoscope Analysis software V1.40 (Bruker USA). AFM images were 
collected from two different samples and at random spot surface sampling. 
2.7 Differential Scanning Calorimetry (DSC) 
Differential scanning calorimetry (DSC) was carried out using a Mettler Toledo DSC822 in 
order to examine the thermal properties of the electrospun PLA scaffolds. First, the 
scaffolds were cut, weighed and placed in the DSC specific aluminium discs. The disc was 
then sealed using a press and subsequently placed in the DSC instrument. The parameters 
for DSC analysis were set (parameters are detailed below) via the computer software. The 
analysis was then run which took approximately 20 min. The method included heating from 
25 °C to 220 °C at 10 °C steps, using standard 40 μl aluminium discs, and each sample 
consisted of 4 mg. 
2.8 X-Ray Powder Diffraction (XRPD) 
XRPD was performed in a Bruker D2 Phaser machine and measurements were taken under 
CuKα radiation (λ= 1.5406 Å), 40 kV and 30 mA as X-ray source with Kb (Ni) filter. Diffraction 
patterns were collected with 2θ ranging from 3° to 70°.  
2.9 Contact Angle Goniometry (CAG) 
To monitor changes in wettability of the scaffolds, sessile drop contact angle for distilled 
water was measured by contact angle goniometry, using a contact angle goniometer (Kruss 
G30, Germany)24. 
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2.10 Surface Energy Analysis 
The dispersive surface energy of the raw drug samples was determined by inverse gas 
chromatography using a SEA–IGC (Surface Measurement Systems). The samples were 
packed into 30 cm (3 mm inside diameter) silanised glass columns, plugged at either end by 
silanised glass wool. Various dispersive probes were used; undecane, decane, nonane, 
octane, heptane, and hexane were injected at a range of fractional surface coverage in 
order to determine the concentration free dispersive surface energy25.  
2.11 1H NMR Studies 
NMR spectra were recorded on a Varian 600 MHz spectrometer at 298.2 ±0.1 K with 
CDCl3:DMF (N,N-dimethylformamide), 95:5, V/V% as solvent, using tetramethylsilane (TMS) 
as the chemical shift reference compound. The sample volume was 600 μL. 1H NMR spectra 
were recorded with the pulse and acquire sequence (number of transients=16, number of 
points=16384, acquisition time=851.968 ms, relaxation delay=1.5 s). 
2.12 In Vitro Drug Release Studies 
The drug releases of the irgasan/levofloxacin loaded PLA-blend scaffolds were measured in 
order to determine the release profile for each drug. Buffer solutions consisting of 
phosphate buffer solution (PBS, pH 7.4) was mixed with 1% sodium dodecyl sulphate (SDS, a 
surfactant was used due to the hydrophobic nature of irgasan). The UV absorbance of both 
drugs were measured (irgasan at 280 nm26, and levofloxacin at 293 nm27, respectively) at 
various time points (e.g.  15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 24 h and then every day up to 
192 h). For every measurement 3 ml of solution was taken from the vial (consisting of total 6 
ml PBS) and replaced with fresh 3 ml buffer in order to satisfy the perfect-sink conditions. 
The samples were stored in a temperature room of 37 ºC. 
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2.13 Antibacterial Studies 
The antibacterial efficacy of the drug loaded electrospun scaffolds were tested with 
Escherichia coli (E. coli) 8739 and Staphylococcus aureus (S. aureus) 29213, bacterial strains 
representative of gram-negative and gram-positive bacteria, respectively.  For this study, a 
disc agar diffusion method was used. Luria-Bertani (LB) agar was prepared with the LB 
medium consisting of 5 g tryptone, 2.5 g yeast extract, 5 g NaCl and 475 ml of deionized 
water. The E. coli and S. aureus cultures were grown overnight in 5 ml of solution, with both 
bacteria inoculated from a single colony. 150 µL of the E. coli and S. aureus cultures were 
spread onto plates of LB agar. 6 plates received an E. coli inoculum, and the other 6 plates 
contained the S. aureus inoculum, before adding small pieces of scaffold onto each plate. 
Scaffolds containing no drug and no scaffold presence acted as controls. Each scaffold was 
placed in triplicate to ensure accurate results. The plates were left for incubation for 48 h, 
and subsequently examined at 24 h and 48 h. Diameters of zones in which there was no 
bacterial growth were measured, and these were compared across the various drugs and 
bacterial strains.  
2.14 Time of Flight Secondary Ion Mass Spectrometry (ToF-SIMS) 
The analyses were carried out with a ToF-SIMS V instrument (ION-TOF GmbH, Münster, 
Germany) equipped with a Bismuth cluster Liquid Metal Ion Gun (LMIG). To overcome 
charge build-up on the isolative samples, a low-energy electron beam (21 eV) flood gun was 
employed and the sample surface potential was optimised for each analysis. 
Spectrometry mode was applied to acquire reference spectra of Levofloxacin, Irgasan and 
PLA. Data was recorded in three replicates for both polarities and each acquisition was 
made from different areas of the samples used in this study, over a field of view of 100 μm × 
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100 μm. The 30 kV Bi3+ primary ion beam was optimised to deliver a final primary ion dose 
density (PIDD) of 8.0 × 1012 (primary ions/cm2) for each spectrum.  
High lateral resolution images of the four drug-loaded samples were collected over a 
surface area of 50 μm × 50 μm, with a resolution of 512x512 pixels (pixel width was circa 0.1 
μm), in the negative secondary ion polarity, with a final PIDD equal to 8.0 × 1012 primary 
ions/cm2. The images were then processed using SurfaceLab 6.7 software (ION-TOF, 
Münster, Germany). All the mass spectral information was recorded in the m/z range of 0 - 
900 Da. 
3. RESULTS 
3.1 Intermolecular Interactions 
Preliminary 1H NMR study performed in liquid phase suggests the absence of any specific 
intermolecular interaction between PLA and LEVO. The 1H NMR spectrum of polylactic 
revealed two well-defined peaks centered at 5.10 and 1.52 (ppm) with smaller peaks 
residing in the vicinity of the main signal (less than 2% in total peak area based on Lorentz 
peak fitting) as depicted in Figure 1. The relatively sharp (2-3 Hz half width) and uniform 
quartet and doublet signals of polylactic acid indicate a well-defined conformation 
throughout the polymer chain, and albeit the varying chain length the chemical 
environment of most monomer units is implied to be highly similar allowing for high 
mobility on account of the narrow peaks, i.e. high T2. The peaks at 7.26, 7.94, 2.89, and 2.81 
are that of CHCl3, the formyl hydrogen of DMF, and the two methyl peaks of DMF, 
respectively. The 1H NMR spectrum of polylactic acid doped with 0.1% levofloxacin showed 
no difference in the NMR parameters of the polymer; the peaks of levofloxacin were 
detected at the expected chemical shift ranges, however these signals appeared with too 
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low SNR to be useful for further measurements. It can only be inferred from the NMR 
measurements that a possible presence of intermolecular interaction between polylactic 
acid and levofloxacin does not bring about detectable changes in the 1H NMR spectra. 
3.2 Fibre Morphology 
A one-way between-groups analysis of variance (ANOVA) indicated that there are significant 
differences (p<0.001) between the investigated formulations. Applying Scheffé post-hoc 
comparison, significant differences were confirmed between samples except for PLA 
compared with PLA-IRG and PLA-Collagen compared with PLA-Collagen-IRG. The latter was 
also corroborated by the overlap between the obtained confidence intervals; whilst in case 
of the other samples the confidence intervals are separated from each other. Except for 
PLA-Collagen-LEVO, 99.7 % of the measured fibre diameters fall between the range of mean 
± 3 SD, and similarities of the mean and median values suggest that these samples are 
normally distributed (Figure 2). 
Fibre diameter histograms were assayed using Kolgomorov-Smirnov test (p<0.01) of equality 
of distributions (Table 2), which indicated that there is no significant difference, when PLA 
compared with PLA-IRG; and PLA-Collagen compared with PLA-Collagen-IRG. On the other 
hand, distributions of PLA/PLA-IRG; PLA-Collagen/PLA-Collagen-IRG; PLA-LEVO; PLA-
Collagen-LEVO were significantly different when compared with each other. It must be 
noted that PLA-Collagen-LEVO exhibited the highest coefficient of variation (72.7 %), whilst 
PLA-LEVO had the lowest value (17.2 %) (Table 1). 
The SEM images (Figure 3) demonstrated a range of morphologies across both polymer-drug 
and polymer-collagen-drug electrospun scaffolds. The PLA-drug scaffolds (Figure 3a – 3c) 
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showed consistent fibre diameter and the addition of IRG and LEVO caused very slight 
beading within the fibres.  
The AFM images (Figure 4) show the morphology of the fibres at a greater detail and 
resolution. PLA-drug scaffolds (Figure 4a – 4b) show a slight variation of morphology across 
their surfaces; PLA fibres have a relatively smooth surface with what appears to be beading 
(possible solvent residue) on the surface, PLA-IRG fibres generally showed smooth 
morphology with no signs of active pharmaceutical ingredient (API) or solvent residue on 
the surface, whereas the PLA-LEVO fibres showed a rougher morphology which may have 
resulted from crystals of the drug at the surface – this observation was supported by the 
release profile (see: Results, Drug Efficacy). The surface morphology for the PLA-collagen-
drug scaffolds (Figure 4d – 4f) showed the presence of collagen “wrapping” the polymeric 
fibres in a helical manner. This morphology was consistent throughout, which may highlight 
a helical coating of the collagen through the fabricated scaffolds. There appeared to be no 
presence of drug on the surface of these fibres.  
3.3 Solid State Characterisation 
The graphs in figure 4 indicate the various DSC isotherms for PLA-drug fibres (Figure 5a), and 
PLA-Collagen fibres (Figure 5b). For most of the samples, the glass transition temperature 
(Tg) is observed around 60°C, the crystallisation temperature (Tc), an exothermic peak, is 
observed around 90 - 115°C and the melting point, an endothermic peak, is observed at 
~145°C. Overall the Tc for PLA-drug samples is lower than the PLA-collagen-drug samples. In 
the case of PLA-IRG (Figure 5a), the Tg appears to be suppressed and a Tc was not measured 
at all.   
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XRPD data shown in figure 5 indicate that PLA fibres are semi-crystalline, indicated by broad 
region, followed by a sharp peak at ~17°. It can be observed in Figure 6a that the addition of 
IRG causes an increase in the crystallinity of the polymer-drug sample, due to the sharp 
polymer peak at ~17°. There are no significant peaks arising within the PLA-IRG graph 
related to the IRG intensity. The PLA-collagen-IRG graph indicates that the sample is in an 
amorphous state, due to the very broad peak observed from ~5° to ~25°. The graphs 
relating to the PLA-LEVO sample (figure 5b) show two significant peaks at ~7° (relating 
levofloxacin) and ~17° (relating to PLA). Again, the addition of collagen to these samples 
resulted in a broad amorphous peak ranging from ~5° to ~25°. 
3.4 Surface Analysis 
The dispersive surface energy of powder irgasan was measured at 37.32 mJ/m2, and a BET 
specific surface area of 0.0103 m2/g. Levofloxacin had a higher dispersive surface energy of 
47.34 mJ/m2 and a BET specific surface area of 0.0481 m2/g. 
The contact angle measurements shown in Figure 7 highlight the differences across PLA-
drug and PLA-collagen-drug combinations; PLA-LEVO had a lower overall starting and 
finishing contact angle (108° ±2.11 to 50° ±2.35 , respectively), compared with the PLA and 
PLA-IRG (120° ±1.09 to 80° ±1.22 , respectively). The samples containing collagen had a 
greater starting contact angle (130° ±3.42) and final contact angle reading (120° ±4.12). 
3.4 Drug Efficacy and Antibacterial Studies 
The cumulative drug release profiles are presented in Figure 8; both PLA-IRG and PLA-
collagen-IRG samples exhibited sustained release behaviour over 192 h, with a final release 
of ~40%. PLA-LEVO exhibited burst release behaviour, releasing ~20% within the first 24 h of 
measurement. PLA-collagen-LEVO showed a significantly lower release percentage initially, 
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however it appeared to exhibit sustained release behaviour, with a final cumulative release 
of 25%.  The total drug content was determined by Concentration × Volume of Medium × 
Dilution Factor / 1000 (correction factor). Therefore, % Drug Release = Amount of Drug / 
Theoretical Drug Amount × 100.  
Antibacterial measurements were taken at 24 h and 48 h (Figure 9, 48 h only). The PLA-drug 
samples show a high efficacy to control the growth of both E. coli and S. aureus. In 
particular, PLA-LEVO (2.1 cm) had a higher average inhibition zone than PLA-IRG (1.0 cm). 
PLA-collagen-IRG resisted both strains of bacteria in a similar manner to the PLA-IRG sample 
(average inhibition zone = 1.1 cm). Finally, the PLA-collagen-LEVO sample showed an 
average inhibition zone to E. coli of 1.0 cm; however white spores of bacteria were re-
forming near the sample. This sample also had a smaller efficacy with inhibiting the growth 
of S. aureus, demonstrating an average inhibition zone of 0.4 cm. 
3.5 ToF-SIMS 
Imaging data showed a difference in the distribution of the APIs in the various strands. The 
compounds of interest are identified by unique characteristic ion peaks; PLA at m/z 71 
([C3H3O2]-) and m/z 89 ([C3H5O3]-), Levofloxacin at m/z 360 ([C18H19FN3O4]-, [M-H]-) and m/z 
316 ([C17H19FN3O2]-), and Irgasan at m/z 287 ([C12H635Cl3O2]- [M-H]-), and isotopes m/z 289 
([C12H635Cl237ClO2]-) and m/z 291 ([C12H635Cl37Cl2O2]-). The total ion images and the overlays 
of single ion images for the characteristic peaks of PLA, PLA-collagen and the two drugs are 
reported in Figure 10. With regards to the PLA-IRG and PLA-LEVO electrospun scaffolds, by 
the ion images Irgasan appears to be homogeneously distributed throughout the sample, 
whilst the presence of Levofloxacin is concentrated in multiple small regions on the surface 
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of the fibers. This confirms the data obtained with the AFM analysis and with the release 
study – (see: Results, Fibre Morphology and Results, Drug Efficacy). 
The diagnostic peaks for both the APIs in the PLA-collagen-API samples present normalized 
intensities which are 2 to 3 times lower than the corresponding peaks in the PLA-API 
samples, making it difficult to comment on their distribution. The reduced signal could be 
caused by matrix effects, an artefact of ionization. Here, it is possible that the presence of 
collagen in the system suppressed the ionization of the APIs.  Alternatively, it could suggest 
a lower concentration of the APIs present on the surface of the PLA-Collagen fibres 
compared to the PLA ones, and could be interpreted as a better embedding of the APIs into 
the strands. 
4. DISCUSSION 
4.1 Fibre Morphology 
The differences in fibre form between PLA-drug and PLA-collagen-drug samples can be 
clearly seen in figures 2 and 3, where the addition of collagen has created smaller diameters 
of the fibres. This is due to the nature of collagen fibre formation, which usually form 
nanofibres of around 100 nm28. Although, the fibres created in this study are significantly 
bigger than other studies (e.g. average collagen fibres diameters = ~400 nm10) this may be 
largely due to the blend of PLA and collagen – with PLA-drug solutions producing fibres with 
a diameter greater than 2 µm. Fibre formation may also be more effective with collagen, 
due to the HFP solvent; the low boiling point (58.2 °C) of this solvent allows for a quicker 
evaporation during the electrospinning process, which in turn means that the fibres are 
being deposited in a dry state. HFP is also a denaturing organic solvent, and therefore the 
interaction between solvent and collagen may cause change in the structure of the 
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proteins29. When compared to polycaprolactone fibres (as conducted in our previous study) 
electrospun in similar conditions, the addition of levofloxacin increased the overall average 
fibre diameter (PCL = ~1.83 µm8 PCL-LEVO = ~2.8 µm22). 
 It was also observed that the addition of levofloxacin within both PLA and PLA-collagen 
blends resulted in a decreased average fibre diameter; this can be linked to the rheological 
behaviour of the solutions where levofloxacin increased the viscosity of the solution, which 
normally results in a change in fibre size30. There also appears to be evidence of levofloxacin 
appearing at the surface of the fibres (figure 4c), however this may be expected for this 
particular drug due to the high dispersive surface energy (see Results: Surface Analysis). If 
the drug has a high surface energy, this affects the viscosity of the solution, which in turn 
alters the surface tension.  
The AFM images of the polymer-collagen blends revealed a helical pattern of collagen 
around the fibres – the fibrils of collagen exhibit a repeating, nano-banding pattern. 
Collagen naturally forms a coiled structure, and the underlying alpha chains within the 
collagen fibrils could be responsible for the repeating banding pattern observed 31. This may 
be useful within a tissue engineering context, given that this repeat banding is thought to 
expose a binding site in the native collagen fibril that enhances cell adhesion and migration6. 
4.2 Solid State Characterisation 
The DSC data was vital in understanding any potential chemical interactions between the 
drug and polymer. In figure 5, the PLA-IRG plot, shows that there is no visible exothermic 
reaction (Tc) occurring after the initial glass transition phase, and also no indication of the Tm 
of the raw IRG drug at around 60 °C – this can interpreted as the IRG being fully integrated 
within the polymeric structure32. The Tc values recorded were greater in the samples 
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containing collagen which may be attributed to dehydration of the collagen33. This may be 
indicative of the collagen successfully embedding or interacting with the polymer. A 
reduction in the Tg at around 60 °C of the PLA-Collagen-LEVO can be observed, which again 
may indicate that there is no presence of free LEVO particle in this sample – this is perhaps 
why a sustained release behaviour is observed in section 4.4 (drug efficacy).  
The data presented by the DSC was effectively confirmed through the XRPD data (figure 6).  
The PLA-IRG sample can be seen to remain in a near semi-crystalline form (slight broad 
peak, followed by sharp crystalline PLA peak), with no IRG peaks. It can be concluded from 
this that the IRG is fully embedded within the polymeric network. Similarly, no IRG peaks 
were visible within the PLA-collagen-IRG graph; however, the broad peak does indicate that 
the material is in an amorphous form. The PLA-LEVO graph showed a peak, indicating that 
the drug is still in crystalline form and is not incorporated uniformly into the polymeric 
network. A similar amorphous peak was observed in the PLA-collagen-LEVO peak, which 
may indicate a better encapsulation of drug.  
4.3 Surface Analysis 
Understanding the surface energy of the drug molecules was an important part of this 
study, since it has successfully helped to understand the reasons behind particular 
behaviour relating to fibre morphology and overall drug encapsulation. The surface energy 
analysis of the two drugs indicated a higher dispersive surface energy for levofloxacin 
compared with irgasan. Given that IRG and LEVO are both in a crystalline form, and that 
polylactic acid is naturally semi-crystalline, there may be an increased possibility of the two 
drugs integrating into the polymeric matrix. The two drugs may require a higher energy in 
order to disperse properly within the PLA polymeric structure. With irgasan having a lower 
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dispersive surface energy and a hydrophobic nature, there may be a reduced energy 
requirement for this drug to properly disperse within a solvent solution. If levofloxacin has a 
higher dispersive surface energy, then the transfer of energy between LEVO and solvent will 
be insufficient to overcome the drug-drug attractions.  Therefore, not all the levofloxacin 
molecules in solution will be surrounded by solvent molecules and dispersed fully into 
solution34. At equilibrium, hydrophobic molecules preferentially partition into the organic 
phase, typically due to a high log P value35 - the log P of levofloxacin is 1.2736 and the log P 
of Irgasan is 4.7637.  Based on the positive values on the log P, both drugs are hydrophobic 
and Irgasan is more hydrophobic than LEVO. With both drugs and PLA exhibiting a 
hydrophobic nature, this suggests that hydrophobic interactions might occur between the 
materials. If the hydrophobic interactions are a dominant, this should be more 
advantageous in increasing encapsulation efficiency38. 
The change in contract angle may reflect the encapsulation of both drugs within the 
polymer matrix. It can be clearly seen in figure 7 that the contact angle was lowest for the 
PLA-LEVO sample. This can be attributed to the lower hydrophobic nature of levofloxacin, 
the high dispersive surface energy and the probability of the drug on the surface of the 
fibres (see Results: Fibre Morphology, AFM). With the PLA-collagen-drug samples, the 
contact angles are greater, implying that the samples are more hydrophobic. These results 
differ from the contact angle measurements in other studies, in particular collagen is found 
to have previously increased the hydrophilicity of PLA samples39. It may be the case that the 
collagen fibrils have interacted within the polylactic acid based nanofibre. This strong 
hydrophobic connection may be linked to the better integration of both irgasan and 
levofloxacin.  
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4.4 Drug Efficacy 
The release profiles of both irgasan and levofloxacin are similar to the results in a previous 
study using polycaprolactone22. However, the final cumulative release percentages with 
Polylactic acid appear to be lower (Final PCL scaffolds drug release ~50%, PLA scaffolds 
~20% to 40%). This may suggest a poorer drug encapsulation with PLA, which may be due to 
the fact that PLA is more hydrophilic than PCL40. The hydrophobic interactions between PLA 
and IRG may potentially be the cause of the sustained release behaviour in vitro, and the 
lower hydrophobic nature of LEVO may be an even further reduction in a strong polymer-
drug interaction. As mentioned in the surface analysis section, the higher dispersive surface 
energy may cause this weak interaction between PLA and LEVO; AFM images in figure 4 
indicating the possible presence of drug at the surface of the fibres. This presence of drug at 
the surface would result in a rapid uptake of water, and therefore be the reason behind the 
burst release behaviour observed in vitro. The addition of type I collagen to the polymer-
drug samples resulted in a difference in release behaviour with LEVO – this drug released in 
a sustained release time profile, implying that collagen may be directly affecting the release 
of the drug. Literature evidence suggests that the hydrophilic, carboxyl functional groups in 
the polymer could be interacting with basic functions expressed by the collagen41 which in 
turn results in a change in the hydrophobicity of the fibre, which may result in the sustained 
release time profile for the levofloxacin with the PLA-collagen sample.  
The antibacterial studies were consistent with the drug release profiles, and indicated that 
the formulations were effective in inhibiting the growth of E. coli and S. aureus. The larger 
zones of inhibition can be seen in the PLA-LEVO sample, which exhibits burst release 
behaviour. The smaller inhibition zones for PLA-IRG and PLA-collagen-IRG were indicative of 
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the sustained release profiles. The sustained release profile of PLA-collagen-LEVO was also 
confirmed, given that there were small areas of bacterial growth – this can be attributed to 
the low cumulative release percentage at 48 h of the study by which time < 10% of the drug 
had been released).  
4.5 ToF-SIMS 
The visualisation of the distribution of the APIs on the sample surface contributed to gain a 
better understanding about the degree of drug encapsulation and in general about the 
interactions between the drugs and the fibres. This result concurs with the suggested 
explanation with regards to the release behaviour and is consistent with the results from 
the other techniques described in this paper. 
5. CONCLUSION 
It can be seen that the inclusion of type I collagen significantly altered various characteristics 
of electrospun polymer-drug scaffolds. The addition of collagen caused an overall decrease 
in fibre morphology and average fibre diameter across both sets of drugs, irgasan and 
levofloxacin, with nanofibers forming in the PLA-collagen-LEVO samples. AFM images 
revealed collagen fibril banding on the surface of the fibres which suggest there is an 
interaction between the polymer-drug and collagen. There were also changes in the solid-
state characteristics of the samples, given that the DSC results indicate an increase in 
amorphousness of the polymer-drug-collagen samples, and this was confirmed through 
typically broad peaks in the XRPD results. Most interestingly, the surface energies of the 
scaffolds were modified with an increase in the hydrophobicity of the polymer-collagen-
drug noted. In particular, the PLA-collagen-LEVO sample showed a high deal of 
hydrophobicity, which was unusual given the low hydrophobic nature of LEVO – this could 
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potentially be attributed to the strong hydrophobic interactions between the PLA and the 
hydrophobic banding in collagen fibrils, resulting in better encapsulation of the drug. Finally, 
the drug release profiles of the samples appear to change due to the inclusion of collagen, 
most significantly demonstrating the shift of the burst release behaviour in PLA-LEVO to 
sustained release behaviour within PLA-collagen-LEVO samples. This study is important in 
demonstrating that the modification of electrospun scaffolds can be achieved by 
incorporating natural polymers, such as collagen – and this modification may be useful in 
the compatibility and utilisation of tissue engineered structures within the human body.  
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Table & Figure Captions.  
Figure 1: The 1H NMR spectrum of polylactic acid in CDCl3:DMF, 95:5, V/V%. 
Figure 2: Histograms of fibre diameters (a) PLA Unloaded, (b) PLA-IRG, (c) PLA-LEVO, (d) PLA-
Collagen (e) PLA-Collagen-IRG, and (f) PLA-Collagen-LEVO. 
Figure 3: SEM Images of: (a) PLA Unloaded, (b) PLA-IRG, (c) PLA-LEVO, (d) PLA-Collagen, (e) 
PLA-Collagen-IRG, and (f) PLA-Collagen-LEVO. 
Figure 4: AFM Images of (a) PLA Unloaded, (b) PLA-IRG, (c) PLA-LEVO, (d) PLA-Collagen (e) 
PLA-Collagen-IRG, and (f) PLA-Collagen-LEVO. 
Figure 5: DSC Curves of (a) PLA-drug, (b) PLA-Collagen-drugs and (c) raw drugs Irgasan and 
Levofloxacin  
Figure 6: XRPD Graphs of (a) PLA IRG Blends and (b) PLA LEVO Blends. 
Figure 7: CAG Data for PLA-Drug and PLA-Collagen-Drug blends. 
Figure 8: Drug release profiles of PLA-drug and PLA-collagen-drug scaffolds. 
Figure 9: Images of antibacterial growth after 48 h. (a) PLA-IRG against E. Coli, (b) PLA-IRG 
against S. Aureus, (c) PLA-LEVO against E. Coli, (d) PLA-LEVO against S. Aureus, (e) PLA-
Collagen-IRG against E. Coli, (f) PLA-Collagen-IRG against S. Aureus, (g) PLA-Collagen-LEVO 
against E. Coli, and (h) PLA-Collagen-LEVO against S. Aureus. 
Figure 10: ToF-SIMS data of (a) PLA-IRG, (b) PLA-LEVO, (c) PLA-Collagen-IRG, and (d) PLA-
Collagen-LEVO 
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 N 
Mea
n 
Std. 
Deviatio
n 
Std. 
Erro
r 
95% 
Confidence 
Interval for 
Mean 
Minimu
m 
Maximu
m 
  
Lowe
r 
Boun
d 
Uppe
r 
Boun
d 
Media
n 
Coefficient 
of  
variation % 
PLA 5
0 
2.73 0.38 0.05 2.62 2.84 1.86 3.62 2.73 30.70 
PLA-IRG 5
0 
2.48 0.64 0.09 2.29 2.66 1.28 3.78 2.42 25.90 
PLA-
LEVO 
5
0 
2.08 0.36 0.05 1.98 2.18 1.32 3.08 2.08 17.20 
PLA-
Collage
n 
5
0 
1.67 0.41 0.06 1.55 1.78 1.06 3.02 1.57 24.47 
PLA-
Collage
n-IRG 
5
0 
1.70 0.50 0.07 1.56 1.84 1.01 3.63 1.64 29.42 
PLA-
Collage
n-LEVO 
5
0 
0.98 0.71 0.10 0.78 1.18 0.12 3.67 0.92 72.67 
 
Table 1 Descriptive statistics of the electrospun fibre diameters. 
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(I) adat 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
PLA PLA-IRG 0.2575600 0.1034985 0.291 -0.089176 0.604296 
PLA-LEVO 0.6521600* 0.1034985 0.000 0.305424 0.998896 
PLA-COLLAGEN 1.0665800* 0.1034985 0.000 0.719844 1.413316 
PLA_COLLAGEN_IRG 1.0354800* 0.1034985 0.000 0.688744 1.382216 
PLA_COLLAGEN_LEVO 1.7551000* 0.1034985 0.000 1.408364 2.101836 
PLA-IRG PLA -0.2575600 0.1034985 0.291 -0.604296 0.089176 
PLA-LEVO 0.3946000* 0.1034985 0.014 0.047864 0.741336 
PLA-COLLAGEN 0.8090200* 0.1034985 0.000 0.462284 1.155756 
PLA_COLLAGEN_IRG 0.7779200* 0.1034985 0.000 0.431184 1.124656 
PLA_COLLAGEN_LEVO 1.4975400* 0.1034985 0.000 1.150804 1.844276 
PLA-LEVO PLA -0.6521600* 0.1034985 0.000 -0.998896 -0.305424 
PLA-IRG -0.3946000* 0.1034985 0.014 -0.741336 -0.047864 
PLA-COLLAGEN 0.4144200* 0.1034985 0.008 0.067684 0.761156 
PLA_COLLAGEN_IRG 0.3833200* 0.1034985 0.019 0.036584 0.730056 
PLA_COLLAGEN_LEVO 1.1029400* 0.1034985 0.000 0.756204 1.449676 
PLA-COLLAGEN PLA -1.0665800* 0.1034985 0.000 -1.413316 -0.719844 
PLA-IRG -0.8090200* 0.1034985 0.000 -1.155756 -0.462284 
PLA-LEVO -0.4144200* 0.1034985 0.008 -0.761156 -0.067684 
PLA_COLLAGEN_IRG -0.0311000 0.1034985 1.000 -0.377836 0.315636 
PLA_COLLAGEN_LEVO 0.6885200* 0.1034985 0.000 0.341784 1.035256 
PLA_COLLAGEN_IRG PLA -1.0354800* 0.1034985 0.000 -1.382216 -0.688744 
PLA-IRG -0.7779200* 0.1034985 0.000 -1.124656 -0.431184 
PLA-LEVO -0.3833200* 0.1034985 0.019 -0.730056 -0.036584 
PLA-COLLAGEN 0.0311000 0.1034985 1.000 -0.315636 0.377836 
PLA_COLLAGEN_LEVO 0.7196200* 0.1034985 0.000 0.372884 1.066356 
PLA_COLLAGEN_LEVO PLA -1.7551000* 0.1034985 0.000 -2.101836 -1.408364 
PLA-IRG -1.4975400* 0.1034985 0.000 -1.844276 -1.150804 
PLA-LEVO -1.1029400* 0.1034985 0.000 -1.449676 -0.756204 
PLA-COLLAGEN -0.6885200* 0.1034985 0.000 -1.035256 -0.341784 
PLA_COLLAGEN_IRG -0.7196200* 0.1034985 0.000 -1.066356 -0.372884 
*. The mean difference is significant at the 0.05 level. 
Table 2 Multiple Comparisons. 
 
 
